ACA
GILD icon

Aptus Capital Advisors’s Gilead Sciences GILD Stock Holding History

Aptus Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-900,000
Closed -$53.5M – 689
2022
Q1 		$53.5M Buy
+900,000
New +$57.5M 1.33% 19

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Aptus Capital Advisors's GILD Position: Q1 2026 in Review

Aptus Capital Advisors reduced its Gilead Sciences (GILD) stake by 5.5% in Q1 2026, selling an estimated $616K and leaving 75,380 shares worth $10.5M. The position accounts for 0.08% of the portfolio, ranked #199.

Aptus Capital Advisors first reported a position in GILD in Q4 2018 and has held it in 23 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Aptus Capital Advisors held 75,380 shares of Gilead Sciences worth $10.5M as of Q1 2026.
  • Aptus Capital Advisors sold 4,402 Gilead Sciences shares in Q1 2026, an estimated $616K.
  • Gilead Sciences made up 0.08% of Aptus Capital Advisors's portfolio in Q1 2026, its #199 holding.
  • Aptus Capital Advisors first reported a position in Gilead Sciences in Q4 2018 and has held it in 23 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Aptus Capital Advisors's 13F filing for Q1 2026, filed 11 May 2026.